Next Article in Journal
Design and Implementation of a Community-Based Exercise Program for Breast Cancer Patients
Previous Article in Journal
Recommendations for the Referral of Patients for Proton-Beam Therapy, an Alberta Health Services Report: A Model for Canada?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 21
Issue 5
10.3747/co.21.2128
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review

by
J.S. Hoch
1,*,
M.B. Brown
2,
C. McMahon
3,
J. Nanson
3,4 and
L. Rozmovits
5
1
Pharmacoeconomics Research Unit, Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; Institute for Health Policy, Management and Evaluation, University of Toronto; and Centre for Excellence in Economic Analysis Research, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON, Canada
2
Department of Philosophy, University of Leth-bridge, Lethbridge, AB, Canada
3
Expert Review Committee, Pan-Canadian Oncology Drug Review, Toronto, ON, Canada
4
Department of Psychology, University of Saskatchewan, Saskatoon, SK, Canada
5
Pharmacoeconomics Research Unit, Cancer Care Ontario, and Qualitative Research, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(5), 263-266; https://doi.org/10.3747/co.21.2128
Submission received: 3 July 2014 / Revised: 5 August 2014 / Accepted: 11 September 2014 / Published: 1 October 2014

Abstract

In this interview with the patient representatives on the Expert Review Committee (pERC) of the Pan-Canadian Oncology Drug Review (pCODR), those representatives offer their views about how to be a valuable contributing member of Canada’s national cancer drug funding recommendation committee. The article seeks to inform readers, and especially clinicians, about pCODR from the perspective of the patient representatives.
Keywords: oncology drug funding; pcodr; health economics oncology drug funding; pcodr; health economics

Share and Cite

MDPI and ACS Style

Hoch, J.S.; Brown, M.B.; McMahon, C.; Nanson, J.; Rozmovits, L. Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review. Curr. Oncol. 2014, 21, 263-266. https://doi.org/10.3747/co.21.2128

AMA Style

Hoch JS, Brown MB, McMahon C, Nanson J, Rozmovits L. Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review. Current Oncology. 2014; 21(5):263-266. https://doi.org/10.3747/co.21.2128

Chicago/Turabian Style

Hoch, J.S., M.B. Brown, C. McMahon, J. Nanson, and L. Rozmovits. 2014. "Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review" Current Oncology 21, no. 5: 263-266. https://doi.org/10.3747/co.21.2128

Article Metrics

Back to TopTop